Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.63 |
| ▸ | CDK4 | P11802 | 1/20 | 0.63 |
| ▸ | CCND1 | P24385 | 1/20 | 0.63 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | PTPRC | P08575 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 5/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504831 | 1.00 | CCNE2 (0.63) | CCNE2CDK4CCND1CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL29664072 | 0.98 | CCNE2 (0.61) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL3600677 | 0.79 | KDM4E (0.46) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL19751957 | 0.79 | GSK3B (0.50) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL28101377 | 0.78 | CDK4 (0.43) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL2954257 | 0.78 | GSK3B (0.43) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL30319849 | 0.78 | CCNE2 (1.00) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL5686048 | 0.78 | CCNE2 (1.00) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL5911539 | 0.77 | CAMK2D (0.62) | — | |
| SCHEMBL28101209 | 0.76 | GSK3B (0.38) | CCNE2CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | claimed |
| EP-3024928-A1 | SMALL MOLECULE BASED CONVERSION OF SOMATIC CELLS INTO NEURAL CREST CELLS | F. Hoffmann-La Roche AG (CH) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015011031-A1 | SMALL MOLECULE BASED CONVERSION OF SOMATIC CELLS INTO NEURAL CREST CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| US-7151108-B2 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATORIES SERVIER (FR) | 2006-12-19 | — | — | US | disclosed |
| EP-1411057-B1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATOIRES SERVIER (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1411057-A1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-04-21 | — | — | EP | disclosed |
| EP-0540956-B1 | Process for the manufacture of substituted maleimides | HOFFMANN LA ROCHE (CH) | 1997-09-03 | — | — | EP | disclosed |
| US-5399712-A | Protein kinase C inhibitor | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | XDH, TOP2A, TOP1 | CCNE2 379/4885CDK4 1989/4885CCND1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.